PMID- 28303056
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20221207
IS  - 0027-7622 (Print)
IS  - 2186-3326 (Electronic)
IS  - 0027-7622 (Linking)
VI  - 79
IP  - 1
DP  - 2017 Feb
TI  - Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in 
      Japanese patients with type 2 diabetes mellitus independent of body mass index.
PG  - 9-16
LID - 10.18999/nagjms.79.1.9 [doi]
AB  - This study investigated the effects of switching from combination therapy with 
      either alogliptin (Alo) or pioglitazone (Pio) to fixed-dose combination therapy 
      (FDCT) with alogliptin and pioglitazone (Alo-Pio FDCT). The usefulness and 
      efficacy of Alo-Pio FDCT were investigated. A total of 50 outpatients with type 2 
      diabetes mellitus (T2DM) treated with Alo and 47 outpatients with T2DM treated 
      with Pio were switched to Alo-Pio FDCT, and its efficacy and usefulness were 
      evaluated. Significant improvements were observed in hemoglobinA1c (HbA(1c)), 
      alanine transaminase (ALT), and gamma-glutamyl transpeptidase (GGT) levels after 
      switching to Alo-Pio FDCT for 16 weeks in both groups. Only the group switching 
      from Alo to Alo-Pio FDCT showed significant improvements in high-density 
      lipoprotein cholesterol (HDL) levels and triglyceride levels. In a multivariate 
      logistic regression model of the variation in the change of HbA(1c) at 16 weeks, 
      ALT and GGT were independent predictors of the change of HbA(1c) at 16 weeks. In 
      addition, the switch to Alo-Pio FDCT improved glycemic control to a certain 
      degree regardless of BMI. Switching from either Alo or Pio to Alo-PIO FDCT may, 
      unlike monotherapy with a DPP-4 inhibitor, be effective for patients with T2DM 
      regardless of whether they are obese or lean.
FAU - Aoki, Chie
AU  - Aoki C
AD  - Department of Endocrinology and Metabolism, Dokkyo Medical University, 
      Shimotugagun, Japan.
FAU - Suzuki, Kunihiro
AU  - Suzuki K
AD  - Department of Endocrinology and Metabolism, Dokkyo Medical University, 
      Shimotugagun, Japan.
FAU - Kuroda, Hisamoto
AU  - Kuroda H
AD  - Department of Endocrinology and Metabolism, Dokkyo Medical University, 
      Shimotugagun, Japan; Green Clinic, Shimotugagun, Japan.
FAU - Sagara, Masaaki
AU  - Sagara M
AD  - Department of Endocrinology and Metabolism, Dokkyo Medical University, 
      Shimotugagun, Japan.
FAU - Shimizu, Masanori
AU  - Shimizu M
AD  - Department of Endocrinology and Metabolism, Dokkyo Medical University, 
      Shimotugagun, Japan.
FAU - Kasai, Kikuo
AU  - Kasai K
AD  - Ishibasi General Hospital, Shimotuke, Japan.
FAU - Aso, Yoshimasa
AU  - Aso Y
AD  - Department of Endocrinology and Metabolism, Dokkyo Medical University, 
      Shimotugagun, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Japan
TA  - Nagoya J Med Sci
JT  - Nagoya journal of medical science
JID - 0412011
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Piperidines)
RN  - 56HH86ZVCT (Uracil)
RN  - EC 2.3.2.2 (gamma-Glutamyltransferase)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - JHC049LO86 (alogliptin)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Aged
MH  - Alanine Transaminase/blood
MH  - Blood Glucose/*drug effects
MH  - Body Mass Index
MH  - Cholesterol, HDL/blood
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone/*therapeutic use
MH  - Piperidines/*therapeutic use
MH  - Uracil/*analogs & derivatives/therapeutic use
MH  - gamma-Glutamyltransferase/blood
PMC - PMC5346615
OTO - NOTNLM
OT  - alogliptin
OT  - dipeptidyl peptidase-4 inhibitor
OT  - fixed-dose combination therapy
OT  - pioglitazone
OT  - type 2 diabetes mellitus
EDAT- 2017/03/18 06:00
MHDA- 2018/12/12 06:00
PMCR- 2017/02/01
CRDT- 2017/03/18 06:00
PHST- 2017/03/18 06:00 [entrez]
PHST- 2017/03/18 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/02/01 00:00 [pmc-release]
AID - 10.18999/nagjms.79.1.9 [doi]
PST - ppublish
SO  - Nagoya J Med Sci. 2017 Feb;79(1):9-16. doi: 10.18999/nagjms.79.1.9.